Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT06914895
Active, not recruiting Phase 3

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06914895 · tracked via the Priya Life Science Denmark tracker
Phase
Phase 3
Started
2025-04-25
Last updated
2026-05-12

Condition(s) studied

Type 1 DiabetesObesityOverweight

Investigational drug(s) / intervention(s)

Tirzepatide →Placebo

Tirzepatide: Administered SC

Placebo: Administered SC

Study summary

The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Have type 1 diabetes and on insulin treatment for at least one year prior to screening * Have an HbA1c value of 7.0% to 10.5% inclusive, at screening * Have a body mass index (BMI) of ≥25 kilograms per square meter (kg/m2) at screening * Are of stable weight for at least 90 days prior to screening and agree to not start an intensive diet or exercise program during the study Exclusion Criteria: * Have experienced two or more events requiring hospitalization due to poor glucose control (hyperglycemia or (diabetic ketoacidosis (DKA)) during the period of 180 days prior to screening and until randomization. * Have experienced one or more events of severe hypoglycemia during the period of 90 days prior to screening and until randomization. * Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema * Have had chronic or acute pancreatitis * Have used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 90 days prior to screening

Primary outcome measure(s)

Trial sites (146)

FacilityCityRegionStatus
Sansum Diabetes Research Institute Santa Barbara California
Care Access - Santa Clarita Santa Clarita California
University of Colorado Anschutz Medical Campus Aurora Colorado
Atlanta Diabetes Associates Atlanta Georgia
Orita Clinical Research Decatur Georgia
North Georgia Clinical Research Woodstock Georgia
East-West Medical Research Institute Honolulu Hawaii
Rocky Mountain Clinical Research Idaho Falls Idaho
Southern Illinois University School of Medicine Springfield Illinois
Indiana University Health University Hospital Indianapolis Indiana
Iowa Diabetes and Endocrinology Research Center West Des Moines Iowa
Endocrine and Metabolic Consultants Rockville Maryland
HealthPartners Institute dba International Diabetes Center Minneapolis Minnesota
SKY Integrative Medical Center/SKYCRNG Ridgeland Mississippi
Boeson Research MSO Missoula Montana
Palm Research Center Tenaya Las Vegas Nevada
Palm Research Center Sunset Las Vegas Nevada
Albany Medical College, Division of Community Endocrinology Albany New York
Research Foundation of SUNY - University of Buffalo Buffalo New York
NYC Research New York New York
SUNY Upstate Medical University Syracuse New York
Lucas Research, Inc. Morehead City North Carolina
Care Access - Lima Lima Ohio
Alliance for Multispecialty Research, LLC Norman Oklahoma
Suburban Research Associates West Chester Pennsylvania
Texas Diabetes & Endocrinology, P.A. Austin Texas
Velocity Clinical Research, Dallas Dallas Texas
Tekton Research, LLC. McKinney Texas
Medrasa Clinical Research Wylie Texas
Eastside Research Associates Redmond Washington
Rainier Clinical Research Center Renton Washington
Investigaciones Medicas Imoba Srl Buenos Aires Argentina
Centro de Investigaciones Metabólicas (CINME) Buenos Aires Argentina
CIPREC Buenos Aires Argentina
Consultorio de Investigación Clínica EMO SRL Buenos Aires Argentina
CENUDIAB Buenos Aires Argentina
Instituto de Investigaciones Clínicas Córdoba Córdoba Argentina
Centro Medico Privado San Vicente Diabetes Córdoba Argentina
Centro de Investigaciones Médicas Mar del Plata Mar del Plata Argentina
Instituto Médico Río Cuarto Río Cuarto Argentina

+ 106 more sites — see the full list on the official registry below.

On this site

📄 Mounjaro (tirzepatide) drug profile →

More Eli Lilly and Company trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06914895 on ClinicalTrials.gov ↗ ← All trials in Denmark